The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
TP53-mutation status by gene-expression signature (TP53 signature) and prediction of efficacy of neoadjuvant chemotherapy (NAC) and recurrence after surgery in breast cancer.
Shin Takahashi
No relevant relationships to disclose
Takafumi Fukui
No relevant relationships to disclose
Nobuhisa Gondo
No relevant relationships to disclose
Takanori Ishida
No relevant relationships to disclose
Noriaki Ouchi
No relevant relationships to disclose
Tadashi Nomizu
No relevant relationships to disclose
Yoichiro Kakugawa
No relevant relationships to disclose
Chikashi Ishioka
Research Funding - Chugai Pharma; Daiichi Sankyo; Merck Serono